New kidney drug shows promise in slowing disease
NCT ID NCT07150338
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This completed trial tested a new drug called QRX-3 (Eseronate) in 45 people with chronic kidney disease stages 3 to 5. The goal was to see if it could slow the decline in kidney function and reduce protein in the urine. Researchers measured changes in kidney filtration rate and protein levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (STAGE 3-4) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Premier Kidney clinic
Pasadena, Texas, 77504, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QRX-3 (also called Eseronate)
What this could lead to
If it works, this could point toward a new treatment to slow kidney function loss in people with chronic kidney disease.
What could go wrong
This is a small, completed trial with only 45 participants. Results may not apply to all kidney disease patients, and the drug's safety and effectiveness are not yet proven in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.